BioArctic AB’s (publ) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as sales of Leqembi reached ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Eisai makes it clear that the intention is in part to help support the rollout of Biogen-partnered Leqembi (lecanemab), the first disease-modifying treatment for Alzheimer’s disease, which was ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

Leqembi, from Japan's Eisai and its U.S. partner Biogen, is a rare success in a field accustomed to failed experimental treatments for the incurable condition. The delay in cognitive decline ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

The dementia drug 'Leqembi', developed jointly by Japanese pharmaceutical company Eisai and U.S. Biogen, can be prescribed only after confirming the suitability of the patient using PET-CT scans.

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail ...

Seed Therapeutics, a BeyondSpring (Nasdaq: BYSI) spin-off, has inked a collaboration with Japan’s Eisai (TYO: 4523) to discover, develop and commercialize novel molecular glue degraders for multiple ...

As of 10:51:07 AM GMT+9. Market Open.

1 Day ESAIY 1.00% DJIA -1.69% S&P 500 -1.71% Health Care/Life Sciences -0.37% ...